Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 天美传媒 Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Asthma is a common chronic inflammatory disorder of the airways. It is clinically characterized by bronchial hyperresponsiveness
(BHR), reversible airflow limitation and recurrent episodes of wheezing, shortness of breath, chest tightness, and cough.
Asthma is in fact a complex syndrome with many clinical and inflammatory phenotypes.
A great advancement in asthma treatment occurred in the first decade of the ongoing century with the advent of the so called
biological treatments, that is those treatments that try to block the proteins or molecules originated in cells that in turn will trigger
or modulate asthma cascade. When the purpose is to block intracellular proteins we call it anti-sense therapy since that attempt
is made by the administration of molecules that are short, single-stranded nucleic acids complementary to target messenger RNA
(mRNA), which bind to receptor mRNA with levels of affinity and avidity that can far surpass that shown by traditional drugs
targeting protein receptors. When we plan to block blood circulating, cell or tissue mediators, we use the so called monoclonal
antibodies (mAbs). MAbs represent a form of immunotherapy using passive immunity where preformed antibodies against a
target antigen are injected into the body. Because of their specificity, mAbs can efficiently target an antigen on a cell of interest or in
the serum and block the binding of cytokines, immunoglobulins, hormones or proteins that promote certain unwanted functions
including inflammatory and immune responses. Ultimately, both methods can attenuate the expression of disease-associated
genes. During this session the mechanisms of action as well as the most relevant mAbs already marketed or in advanced state of
development for asthma treatment will be reviewed.
Biography
Christian Domingo is Consultant of Pulmonary Medicine at the Hospital de Sabadell (Corporaci� Parc Taul�, Sabadell, Barcelona, Spain), Professor
of Medicine at the Autonomous University of Barcelona, Professor of the Department of Anatomy and Physiology of the International University of
Catalonia until 2010 and Professor of the Master in Health Economy of the University of Malaga. Dr. Christian Domingo is also Advisor to the Gerson
Lehrman Group and Genatics Group. He is a regular reviewer as well as member of the editorial board of international medical journals and the
Editor-in-Chief of ?The 天美传媒 Respiratory Medicine Journal?.
Christian Domingo studied at the Lyc閑 Fran鏰is of Barcelona and later on received his Medical Degree (M.D.) from the Universitat Aut髇oma in
Barcelona, Spain in 1984. After taking the national board, he was admitted in the Hospital Universitari Germans Trias i Pujol of Badalona (Barcelona)
where he completed his Residency in Pulmonary Medicine from 1986-1989. He was also trained at the Cardio-Pulmonary Transplantation Unit
of the Methodist Hospital in Houston, Texas (USA) and l?Unit� de Soins Intensifs in Lyon (France). Later on, he worked as a staff member of the
Intensive Care UnIt at the Hospital Germans Trias I Pujol for three years, until 1992 when he became the staff member of the Pulmonary Service of
the Corporaci� Parc Taul�.
In addition to memberships and awards for his accomplishments in lung research, Dr. Christian Domingo has obtained more than 500,000 dollars
in grants. He is also the director of several doctoral thesis of pulmonologists, internists and pediatricians and has published more than 90 papers.
During the past 20 years his research has focused mainly in severe asthma and COPD, especially in new treatments.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, 天美传媒 Access Journals
